MDA-MB-231 Xenograft Rat Model Service for Breast Cancer

The MDA-MB-231 xenograft rat model stands as one of the most robust preclinical platforms for interrogating triple-negative breast cancer biology and therapeutic response in a physiologically relevant setting. At Alfa Cytology, we engineer and validate these rat-based xenograft systems with meticulous attention to tumor microenvironment fidelity, enabling our partners to advance novel oncology candidates from early pharmacological profiling through late-stage efficacy benchmarking with confidence and reproducibility.

Overview of MDA-MB-231 Xenograft Rat Model for Breast Cancer

The MDA-MB-231 cell line, originally isolated from the pleural effusion of a 51-year-old female patient with metastatic mammary adenocarcinoma, represents the triple-negative breast cancer (TNBC) subtype characterized by the absence of estrogen receptor (ER), progogen receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. When propagated as a xenograft in immunodeficient rats—most commonly athymic nude (RNU) or severely immunocompromised strains such as Rag2/Il2rg double knockout models—MDA-MB-231 tumors recapitulate key hallmarks of human TNBC, including rapid proliferative kinetics, prominent epithelial-to-mesenchymal transition (EMT), and spontaneous metastatic dissemination to distant organs such as lung, liver, and lymph nodes. The larger body mass and physiological proximity of rats to human cardiovascular and metabolic systems render this model particularly advantageous for longitudinal imaging studies, serial blood sampling, and integrated pharmacokinetic-pharmacodynamic analyses that are technically challenging in murine counterparts.

Fig 1. Inhibitory effects of foretinib on MDA-MB-231 xenograft tumors. (Ji, Xiwei, et al., 2023)

In the preclinical landscape, MDA-MB-231 rat xenografts serve as a cornerstone for evaluating cytotoxic agents, targeted small molecules, antibody-drug conjugates, and emerging immunotherapeutic modalities. Orthotopic implantation into the mammary fat pad—often facilitated by ultrasound-guided injection to ensure precise cell deposition—yields tumor take rates approaching 100% while preserving the native stromal architecture and vascular dynamics observed in human disease. Subcutaneous engraftment, though less anatomically faithful, offers straightforward tumor accessibility and remains widely employed for primary screening cascades. Researchers leverage this model to interrogate tumor growth inhibition (TGI), tumor growth delay (TGD), metastatic latency, biomarker modulation, and combination regimen scheduling, making it an indispensable translational tool in the oncology drug development pipeline.

Cell Line Information: MDA-MB-231

MDA-MB-231 is among the most extensively characterized and frequently utilized breast cancer cell lines in oncology research. The following table summarizes its essential biological and molecular attributes relevant to xenograft model development and therapeutic screening.

Our Services

Alfa Cytology delivers end-to-end MDA-MB-231 xenograft rat model services tailored to the demands of modern preclinical oncology pipelines. From strain selection and orthotopic surgical implantation through longitudinal tumor monitoring, biomarker analysis, and comprehensive histopathological endpoints, our scientific team ensures each study is executed under rigorous quality standards with full traceability. Whether your program requires a standard subcutaneous screening model or a sophisticated ultrasound-guided mammary fat pad engraftment with metastasis tracking, we provide the technical depth and operational flexibility to accelerate your candidate's path toward IND-enabling studies.

Workflow of MDA-MB-231 Xenograft Rat Model Construction

Construction of a reproducible MDA-MB-231 xenograft rat model demands rigorous adherence to cell culture hygiene, precise surgical technique, and standardized monitoring protocols. The workflow below outlines the critical phases from cell preparation through endpoint analysis, ensuring consistent tumor take rates and physiologically meaningful data output.

1. Cell Culture and Quality Control: MDA-MB-231 cells are expanded in RPMI-1640 medium supplemented with 10% FBS under standard incubation conditions (37°C, 5% CO₂). Prior to inoculation, cells undergo authentication via short tandem repeat (STR) profiling and mycoplasma testing to exclude cross-contamination. Passage number is strictly controlled (typically below P15) to minimize genetic drift and preserve metastatic competence.
2. Animal Acclimatization and Strain Selection: Immunodeficient rats—typically athymic nude (RNU) or severely immunocompromised Rag2/Il2rg double knockout strains—are quarantined for a minimum of five days upon receipt. Body weight, clinical signs, and baseline hematological parameters are recorded. Animals are randomized into treatment cohorts based on body mass to minimize inter-group variability.
3. Cell Harvest and Resuspension: At 70–80% confluence, cells are detached using 0.05% trypsin-EDTA, washed in phosphate-buffered saline (PBS), and counted via automated hemocytometer or flow cytometry. Viability is confirmed to exceed 95% by trypan blue exclusion. Cells are resuspended in ice-cold PBS or serum-free medium at a concentration of 1–5 × 10⁶ cells/mL. For enhanced engraftment, cells may be mixed 1:1 with Matrigel or an equivalent basement membrane matrix.
4. Orthotopic or Subcutaneous Implantation: For orthotopic models, a small skin incision is made over the mammary fat pad, and cell suspension (typically 100 µL containing 1–5 × 10⁶ viable cells) is delivered into the mammary fat pad under ultrasound guidance or direct visualization. Subcutaneous models involve flank injection of the same cell suspension without surgical incision. The wound is closed with surgical staples or sutures, and analgesia is administered per institutional guidelines.
5. Post-Operative Monitoring and Tumor Surveillance: Animals are housed in individually ventilated cages under specific pathogen-free (SPF) conditions with daily health observations. Tumor dimensions are measured twice weekly using digital calipers, with volumes calculated via the modified ellipsoid formula: Volume = (length × width²) × 0.5. Body weights and clinical scores are documented concurrently to detect treatment-related toxicity.
6. Therapeutic Intervention and Pharmacokinetic Sampling: Upon reaching a predetermined tumor volume (commonly 100–200 mm³), animals are randomized into vehicle control and treatment arms. Test articles are administered via the designated route—oral gavage, intravenous, intraperitoneal, intratumoral, or continuous infusion—according to the study protocol. Serial blood draws (up to 300 µL per collection in rats) enable pharmacokinetic profiling without compromising animal welfare.
7. Endpoint Analysis and Tissue Procurement: At study termination, animals are humanely euthanized according to IACUC-approved protocols. Primary tumors are excised, weighed, and photographed. Distant organs (lung, liver, lymph nodes, bone) are harvested for metastasis assessment via histology, immunohistochemistry (IHC), and/or quantitative PCR. Tumor tissues are snap-frozen or formalin-fixed for downstream molecular profiling, including RNA sequencing, Western blotting, and multiplex cytokine analysis.

Fig 2. MDA-MB-231 Xenograft Rat Model construction workflow.

Case Study-MDA-MB-231 Xenograft Rat Model Development

In a representative preclinical engagement, female athymic nude rats received orthotopic implantation of MDA-MB-231 cells into the abdominal mammary fat pad under ultrasound guidance, achieving a 100% tumor take rate within two weeks. Tumors exhibited exponential growth kinetics, reaching a mean volume of approximately 800 mm³ by day 21 post-inoculation, with histological examination confirming poorly differentiated adenocarcinoma morphology, extensive necrotic cores, and rim-confined vascularity consistent with human TNBC pathology. A parallel cohort was subjected to combination therapy comprising a cytotoxic agent and an anti-angiogenic compound, resulting in statistically significant tumor growth inhibition relative to vehicle-treated controls, alongside reduced circulating VEGF levels and diminished CD31⁺ microvessel density in excised tumor sections. These findings underscore the translational relevance of the MDA-MB-231 rat xenograft platform for evaluating both monotherapy and combination regimens in the triple-negative breast cancer space.

Why Choose Alfa Cytology?

Selecting the right preclinical CRO partner can determine the trajectory of your oncology program. Alfa Cytology combines deep scientific expertise with operational excellence to deliver MDA-MB-231 xenograft rat model data that withstands regulatory scrutiny and informs critical go/no-go decisions.

• Validated Model Portfolio — Our MDA-MB-231 rat xenografts undergo rigorous qualification including tumor take rate verification, growth kinetics characterization, and positive control benchmarking against standard-of-care agents.
• Multidisciplinary Surgical Expertise — Our veterinary surgeons specialize in ultrasound-guided orthotopic implantation, ensuring precise cell delivery into the mammary fat pad with minimal trauma and maximal reproducibility.
• Integrated Analytical Capabilities — In-house histopathology, immunohistochemistry, flow cytometry, and molecular biology services eliminate external hand-off delays and preserve sample integrity.
• Flexible Study Designs — We accommodate custom dosing schedules, combination arms, multiple administration routes, and specialized endpoints tailored to your compound's mechanism of action and development stage.
• Regulatory-Grade Documentation — All studies are conducted under IACUC oversight with comprehensive protocols, real-time data capture, and audited final reports suitable for IND submissions and investor presentations.
• Dedicated Project Management — Each client is assigned a PhD-level scientific lead who provides weekly progress updates, troubleshoots technical challenges, and ensures alignment with your timeline and budget constraints.

Contact Us

Ready to advance your triple-negative breast cancer program with a validated MDA-MB-231 xenograft rat model? Reach out to us today to discuss your specific study requirements, timeline, and budget. Our scientific team is prepared to design a customized preclinical strategy that aligns with your therapeutic goals and accelerates your path toward IND-enabling data packages. Whether you need a single-arm efficacy study or a multi-cohort combination therapy evaluation, Alfa Cytology stands ready to be your trusted partner in preclinical oncology research.

For research use only. Not intended for any clinical use.